PT-141 10mg
Bremelanotide · melanocortin agonist (MC4R/MC3R) · PRN use
For research use only (RUO)
Ships from Quito · EC 1-3 days · LATAM 4-10
Arrives damaged? We replace it free
COA per batch4 mechanisms. Central pathway, not vascular.
PT-141 acts on the central nervous system — not on peripheral circulation like Viagra/Cialis. That's why it works in both sexes and in cases where PDE5 inhibitors don't respond.
MC4R/MC3R agonist
Activates melanocortin receptors in the hypothalamus. Stimulates the central dopaminergic pathway — desire originates in the brain, not in peripheral circulation.
Works in both sexes
Increases desire and arousal in both men and women. The clinical version (Vyleesi) is FDA-approved for premenopausal female HSDD since 2019.
Responds to mental state
Unlike PDE5 inhibitors (purely vascular), PT-141 also acts on the mental/emotional component of desire. Useful where the cause is psychogenic or mixed.
Independent of testosterone
Does not modify endogenous hormone levels. Compatible with TRT, hormonal peptide cycles (CJC/Ipa), or users with normal T.
Combine with.
PT-141 is used PRN — not in a continuous stack. But certain baseline peptides amplify its contextual effect.
PT-141 must NOT be combined with vasodilators (poppers, simultaneous sildenafil) due to risk of hypotension. If you have any doubts, contact us before starting.
Technical description.
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide, an analog of α-MSH (alpha-melanocyte-stimulating hormone). It acts as an agonist of the MC4R and MC3R melanocortin receptors in the central nervous system — specifically in the hypothalamus, where it stimulates the dopaminergic pathway responsible for sexual desire and arousal.
SuperBio Labs PT-141 is supplied as a lyophilized powder with verified HPLC purity ≥99%. Every batch ships with an independent Certificate of Analysis confirming identity by LC-MS, peptide content (98–102%), and endotoxin levels (<1.0 EU/mg).
The pharmaceutical version of PT-141 (Vyleesi®, Palatin Technologies) has been FDA-approved since 2019 for the treatment of HSDD (hypoactive sexual desire disorder) in premenopausal women. Unlike PDE5 inhibitors (sildenafil, tadalafil) that act peripherally on vasculature, PT-141 acts centrally on desire and arousal. It works in men and women, in psychogenic cases, and where PDE5 inhibitors don't respond or aren't appropriate. Use is PRN (as-needed), not daily.
Producto para uso profesional informado.
Complete kit · ready to reconstitute.
Every order includes everything needed for 10-20 PRN applications. No need to buy anything separately.
How to choose where to buy peptides.
This product meets all five — your batch COA ships with the kit.
Recommended application protocol.
PT-141 is PRN (as-needed use), not daily. It is administered 30-45 min before sexual activity. No continuous protocol required.
ALWAYS start with a 0.5 mg dose to assess individual response and tolerance (especially nausea, the most common side effect). Do NOT combine with poppers, simultaneous sildenafil/tadalafil, or antihypertensive medication without medical consultation.
When to use PT-141.
Female HSDD
Premenopausal hypoactive sexual desire disorder · FDA-approved indication (clinical version).
PDE5 non-responders
Men for whom sildenafil/tadalafil don't work or who have poorly tolerated side effects.
Psychogenic component
Cases where the primary cause is stress, anxiety, or a mental component · central pathway useful.
Adults on TRT
T within range but suboptimal libido · PT-141 acts on an independent dopaminergic pathway.
Post-SSRI
Sexual dysfunction associated with antidepressants · PT-141 can improve response without modifying baseline medication.
Occasional PRN vitality
Sporadic use (dates, travel) · no continuous protocol required · only when needed.
Honest side effects.
The #1 side effect is nausea. It occurs in up to 40% of users on their first dose, generally 30-60 min post-injection and lasting 1-2 hours. That's why you start with a 0.5 mg test dose.
Others: mild facial flushing · occasional headache · slight transient elevation in blood pressure (not recommended for uncontrolled hypertension) · post-effect fatigue · darkening of freckles/moles with very frequent use (cross-MC1R effect · rare). Taking a small dose with a light meal significantly reduces nausea.
Technical specifications
| Product | PT-141 (Bremelanotide) |
| CAS Number | 189691-06-3 |
| Molecular Weight | 1025.16 Da |
| Sequence | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Purity (HPLC) | ≥99% |
| Format | Lyophilized powder |
| Quantity | 10mg per vial |
| Clinical reference | Vyleesi® (Palatin Technologies, FDA 2019) |
| Endotoxins | <1.0 EU/mg |
| Storage | −20 °C, protected from light |
| Use | Uso bajo criterio profesional |